38.44 +0.08 (0.21%)
Pre-Market: 5:47AM EST
|Bid||38.46 x 1000|
|Ask||38.50 x 800|
|Day's Range||38.17 - 39.28|
|52 Week Range||32.69 - 41.78|
|Beta (3Y Monthly)||0.66|
|PE Ratio (TTM)||40.16|
|Forward Dividend & Yield||1.40 (3.58%)|
|1y Target Est||43.04|
Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.
How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca (AZN) reported revenues worth $2.85 billion from China, which is a YoY rise of 33% on an actual basis and 27% on a CER (constant exchange rate) basis. China accounted for around 56% of the company’s total emerging markets sales and 19% of the total revenues earned by the company in the first nine months of 2018.
How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca reported oncology revenues of $4.26 billion, which is a YoY increase of 47% on an actual basis and 44% on a constant exchange rate (or CER) basis. In the first nine months of 2018, AstraZeneca reported new cardiovascular, renal, and metabolism (or CVRM) product sales worth $2.90 billion, which is a YoY rise of 14% on an actual basis and 12% on a CER basis.
- Pyramid Biosciences to exclusively develop AstraZeneca's novel cell surface receptor (TRK) program - Targeting range of dermatological and inflammatory diseases, including psoriasis and atopic dermatitis ...
How Is AstraZeneca Positioned in December? In the third quarter, AstraZeneca (AZN) managed to surpass consensus adjusted EPS estimates by $0.27. In the third quarter, AstraZeneca reported operating profit of $851 million, which is a YoY decline of 26% on an actual basis and 21% on a constant exchange rate (or CER) basis.
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca (AZN) reported selling, general, and administrative (or SG&A) expenses of $7.43 billion, which is a YoY rise of 4% on an actual basis and 1% on a constant exchange rate (or CER) basis. The company reported core SG&A expenses of $6.21 billion in the first nine months of 2018, which is a YoY rise of 10% on an actual basis and 7% on a CER basis.
How Is AstraZeneca Positioned in December? AstraZeneca (AZN) reported a gross margin of 79.8% in the first nine months of 2018, which is a decline of 200 basis points on a YoY basis. Wall Street analysts expect AstraZeneca to report a gross margin of 80.40% in fiscal 2018, which would be a YoY decline of 39 basis points.
How Is AstraZeneca Positioned in December? In its third-quarter earnings conference call, AstraZeneca (AZN) reiterated its core EPS guidance of $3.30–$3.50 at a constant exchange rate (or CER). In the third quarter, AstraZeneca posted core EPS of $0.71, which is a YoY decline of 37% on an actual basis and 33% on a CER basis.
How Is AstraZeneca Positioned in December? On December 11, AstraZeneca (AZN) closed at $38.66, which is 0.65% higher than its previous closing price. AstraZeneca has risen 3.40% from $38.51 on November 1 to $39.82 on November 30.
FDA grants breakthrough device designation to GuardantOMNI test usedfor plasma-based tumor mutational burden analysis in AstraZeneca trial Agreement covers immunotherapy and.
How Is Tesaro Positioned in December? As per GlaxoSmithKline’s (GSK) analyst call transcript, Tesaro’s (TSRO) Zejula is competing with AstraZeneca’s (AZN) Lynparza and Clovis Oncology’s (CLVS) Rubraca as maintenance therapy in the second-line platinum-sensitive ovarian cancer indication. GlaxoSmithKline (GSK) has estimated the annual incidence of these patients in the US market to be around 5,000.
On October 22, 2018, AstraZeneca (AZN) issued a press release announcing positive results from Phase 3 trial SOLO-1, which evaluated PARP inhibitor Lynparza as a first-line maintenance therapy in ovarian cancer patients with germline BRCA (or gBRCA) mutations. The robust data from this trial in terms of improvement in progression-free survival has made a strong case for the advancement of other PARP inhibitors in the maintenance setting for first-line ovarian cancer patients.
The market has been volatile as the Federal Reserve continues its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points through November 16th. SEC filings and hedge fund […]
Moderna (NASDAQ:MRNA) went public on Dec. 7, raising $604 million on a market cap of $7.5 billion. The IPO met the goal, but a bad day on Wall Street sent the shares plummeting. It’s because Moderna represents the next wave in drug discovery. Like Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna is less a bet on particular drugs than on a method for finding them.
Clovis Oncology Inc (NASDAQ: CLVS ) has emerged as a strong takeover candidate following GlaxoSmithKline plc (NYSE: GSK )'s proposed acquisition of TESARO Inc (NASDAQ: TSRO ), according to Gabelli Research. ...
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
The $1.4 billion Moderna lost in value is greater than the market value of more than half the companies in the Nasdaq Biotechnology Index. The company boasts partnerships with sector juggernauts including Merck & Co. and AstraZeneca Plc, so its growth prospects have attracted notable attention across the sector.
The results come after AstraZeneca warned last month that its immunotherapy treatment Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares. AstraZeneca has been seen as having a head start in the race for cancer treatments, and Imfinzi was aiming to be the new standard of care in treating early inoperable stage III lung cancer.